Skip to main content

Table 1 Baseline characteristics a

From: The protective effects of a phosphodiesterase 5 inhibitor, sildenafil, on postresuscitation cardiac dysfunction of cardiac arrest: metabolic evidence from microdialysis

 

Sham group

SA group

Sildenafil group

 

( n  = 8)

( n  = 8)

( n  = 8)

Weight, kg

29.13 ± 2.16

30.63 ± 0.92

30.38 ± 0.92

HR, beats/min

99.00 ± 7.44

101.38 ± 8.30

100.50 ± 10.04

MAP, mmHg

103.12 ± 5.19

101.88 ± 5.22

87.00 ± 5.81

MPAP, mmHg

23.42 ± 4.32

24.13 ± 5.24

24.34 ± 4.56

CO, L/min

2.86 ± 0.22

2.99 ± 0.20

2.99 ± 0.19

DO2, ml/min

424 ± 35

445 ± 34

450 ± 28

VO2, ml/min

112 ± 12

112 ± 9

115 ± 12

ERO2, %

24.17 ± 2.34

25.44 ± 2.70

25.46 ± 1.49

Lac, mmol/L

1.21 ± 0.49

1.31 ± 0.72

1.23 ± 0.01

  1. aValues are mean ± SD. CO, Cardiac output; DO2, Oxygen delivery; ERO2, Extraction of oxygen; HR, Heart rate; Lac, Lactate; MAP, Mean aortic pressure; MPAP, Mean pulmonary arterial pressure; SA, Saline; VO2, Oxygen consumption.